Passage Bio Inc (PASG)
Passage Bio Inc. is a NASDAQ-listed biotechnology company focused on genetic medicines for central nervous system disorders. The company is developing several gene therapy programs, including PBFT02 for frontotemporal dementia linked to progranulin deficiency, PBGM01 for infantile GM1 gangliosidosis, PBKR03 for Krabbe disease, PBML04 for metachromatic leukodystrophy, and PBAL05 for amyotrophic lateral sclerosis. It also has additional programs related to Huntington’s disease. Passage Bio has research and development collaborations with the University of Pennsylvania’s Gene Therapy Program and with Catalent Maryland, which support its clinical and manufacturing activities. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PASG
|
$5.94
|
22.5% Upside
|
Undervalued
|
$15.50
|
219.6% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-0.4x
|
1.3x
|
—
|
15.43 M
|
-12.023 M
|
27.2%
|
90.0%
|
-64.3
|
—
|
81.3%
|
